Company's board approved Q2FY26 results.

Consolidated revenue rose to 645.16 Cr, profit at 20.66 Cr.

Standalone profit was 10.78 Cr.

Key developments include a 7 Cr investment in Cancer Care Kenya and a 9.60 Cr deferred tax credit.

An open offer acquired 318 shares at Rs. 504.41.